NBE-Therapeutics engages in the development of “next-generation” antibody drug conjugates (ADCs) leveraging its proprietary technology platforms for therapeutic antibody and site-specific conjugation technologies. NBE-Therapeutics has the goal to develop best-in-class ADC product candidates until clinical proof-of-concept in patients.